HistoGeneX is now CellCarta Learn More

Webinar: Understanding T-Cell Immunity for COVID-19 Vaccine Responses

Should Assessing T-Cell Response Be an Essential Part of COVID-19 Vaccince Development?


WEBINAR co-sponsored by 70477c53 10b5 4136 ae09 796a25510cff

October 1st, 2020 | 1-2PM ET


Discussions on COVID-19 immune responses, including responses in early vaccine clinical studies, have focused largely on antibody responses. However, recent data indicate that the cellular immune response also plays an important role and should be considered when evaluating the immune response. Assessing T-cell responses can provide critical information about vaccine responses and the development and persistence of protective immunity against SARS-CoV-2 that will be critical in the fight against COVID-19.

Join Scott Gottlieb, MD, 23rd Commissioner of the FDA, and James E. Rothman, PhD, Nobel Laureate, both members of Caprion-HistoGeneX’s scientific advisory board, as well as Eustache Paramithiotis, PhD, our VP of Research & Development, who, during this webinar, will help you recognize the importance of cell immunity in COVID-19-related vaccine development.

Our speakers will discuss:

  • An overview of the current state of COVID-19 vaccine development
  • The adaptive immune response to SARS-CoV-2 and the importance of cellular immunity
  • Testing methods and assay standardization for understanding complex immune system reactions as part of vaccine development programs


278de399 705e 4e45 a29e 39788967a623

Scott Gottlieb, MD
23rd Commissioner of the FDA

Dr. Gottlieb will discuss the implications of immune response testing for overall assessment, regulatory approval, and public acceptance of COVID-19 vaccines.


ba28ca3e 9822 4a3e a6a9 b2e1c22592d9

James E. Rothman, PhD
Nobel Laureate Sterling Professor of Cell Biology and Chair of the Department of Cell Biology at Yale University School of Medicine

Dr. Rothman will provide an overview of the immune response to SARS-CoV-2 and the importance of cellular immunity. The key findings from our previous experiences with SARS-CoV-1, as well as the latest publications, will also be discussed.


9d7d2fa5 ac7e 4747 9330 9add1f18cd5b

Eustache Paramithiotis, PhD
VP of Research & Development Caprion-HistoGeneX

Testing methods for understanding complex immune system reactions as part of vaccine development programs will be discussed by Dr. Paramithiotis. Information on the methodology and accuracy of these assays will be provided.



Caprion - HistoGeneX is a leading provider of specialized precision medicine services to the biopharmaceutical industry including flow and mass cytometry immune monitoring, quantitative mass spectrometry, molecular profiling, as well as quantitative immunohistochemistry. Leveraging its integrated platforms, Caprion-HistoGeneX supports the entire drug development cycle, from discovery to clinical trials. The company operates globally with laboratories located in Canada, USA, Belgium, UK, Australia, and China.

For more information: www.caprion.com and www.histogenex.com